GlassScriptPhysician profile
Jason Shaoul Applebaum
NPI 1447251129
$2,630.37
in general payments reported to CMS, 2019-2025
23 companies · $529 in 2025
The $529 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $150 · 2021: $192 · 2022: $539 · 2023: $229 · 2024: $181 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $656.58 | 2019-2022 | |
| Biotronik INC. | $431.43 | 2019 | |
| Medtronic, INC. | $360.87 | 2025 | Micra, Aurora Ev-Icd Mri Surescan |
| Atricure, INC. | $274.98 | 2022 | |
| Revance Therapeutics, INC. | $137.72 | 2025 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $125.40 | 2022-2023 | Sotyktu |
| Abbvie INC. | $122.69 | 2022-2024 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $72.73 | 2022 | |
| Ge Healthcare | $66.25 | 2024 | |
| Abbott Laboratories | $65.64 | 2022-2024 | Aveir |
| Incyte Corporation | $55.54 | 2023 | Opzelura |
| Ucb, INC. | $55.35 | 2022-2023 | Cimzia |
| Mylan Pharmaceuticals INC. | $24.01 | 2019 | |
| Amgen INC. | $23.98 | 2023 | Otezla |
| Coopersurgical, INC. | $23.84 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $20.26 | 2020 | |
| Celgene Corporation | $19.74 | 2019 | |
| Promius Pharma LLC | $18.62 | 2019 | |
| Krystal Biotech INC | $18.45 | 2023 | Vyjuvek |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.45 | 2024 | Siliq |
| Sun Pharmaceutical Industries INC. | $15.21 | 2025 | |
| Pfizer INC. | $15.21 | 2025 | |
| Biofrontera INC. | $7.42 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Applebaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.